# US 2026/0248748 A1 · Lipooligoureas, pharmaceutical composition, and lipooligoureas for use as medicament

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0248748 A1
- Document ID: US20260248748A1
- Status: Published application
- Kind: A1
- Application number: 18/995,501
- Filed: 2023-07-19
- Published: 2026-08-27
- Earliest claimed: 2022-07-19
- Assignees: Uniwersytet Warszawski
- Applicants: Uniwersytet Warszawski
- Inventors: Slawomir SEK; Karolina PULKA-ZIACH; Joanna JUHANIEWICZ-DEBINSKA; Dariusz BARTOSIK; Robert LASEK; Damian DZIUBAK; Paulina BACHURSKA-SZPALA; Kinga BURDACH
- Web page: https://patentgrep.com/patent/US20260248748A1

## CPC

- A61K 31/17: having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine (isoureas, isothioureas A61K31/155; sulfonylureas A61K31/64)
- C07K 7/02: Linear peptides containing at least one abnormal peptide link
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/02: Inorganic compounds
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 31/04: Antibacterial agents
- C07C 275/24: containing six-membered aromatic rings
- C08G 71/02: Polyureas
- C08L 75/02: Polyureas
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)

## Abstract

The subject matter of the invention is a lipooligourea of the formula (1) FA-Pheu-Xaa1u-Xaa2u-Leuu-Xaa3u-NH2 (1) wherein FA is a linear or branched carboxylic acid residue containing 6 to 15 carbon atoms in the alkyl chain; Xaa1u is either Lysu or Dabu or Argu; Xaa2u is either Lysu or Dabu or Leuu or Argu; Xaa3u is either Lysu or Dabu or Leuu or Argu. The invention also relates to a pharmaceutical composition containing a lipooligourea of formula (1).

## Claims

### Claim 1

A lipooligourea having general formula (1)
wherein
FA is a linear or branched carboxylic acid residue containing 6 to 15 carbon atoms in the alkyl chain;
Xaa1u is either Lysu or Dabu or Argu;
Xaa2u is either Lysu or Dabu or Leuu or Argu;
Xaa3u is either Lysu or Dabu or Leuu or Argu.

### Claim 2 (depends on 1)

The lipooligourea according to claim 1, selected from the group consisting of

### Claim 3 (depends on 1)

The lipooligourea as defined in claim 1 for use as a medicament.

### Claim 4 (depends on 1)

A method of treating a bacterial infection, said method comprising administering a therapeutically effective amount of a lipooligourea as defined in claim 1 to a subject in need thereof.

### Claim 5 (depends on 4)

The method according to claim 4, characterized in that the bacterial infection is caused by either a gram-positive or a gram-negative bacterium.

### Claim 6 (depends on 4)

The method according to claim 4, characterized in that the bacterial infection is caused by a Staphylococcus bacterium.

### Claim 7 (depends on 4)

The method according to claim 4, characterized in that the bacterial infection is caused by Staphylococcus aureus or Staphylococcus epidermidis.

### Claim 8 (depends on 4)

The method according to claim 4, characterized in that the bacterial infection is caused by a strain of methicillin-resistant Staphylococcus aureus (MRSA).

### Claim 9

A method of treating a bacterial infection caused by a strain of methicillin-resistant Staphylococcus aureus (MRSA), said method comprising administering a therapeutically effective amount of a lipooligourea having formula LOU2 or LOU3 to a subject in need thereof

### Claim 10

A pharmaceutical composition, characterized in that it contains a lipooligourea of general formula (1)
wherein
FA is a linear or branched carboxylic acid residue containing 6 to 15 carbon atoms in the alkyl chain;
Xaa1u is either Lysu or Dabu or Argu;
Xaa2u is either Lysu or Dabu or Leuu or Argu;
Xaa3u is either Lysu or Dabu or Leuu or Argu.

### Claim 11 (depends on 10)

The pharmaceutical composition according to claim 10, characterized in that it contains a lipooligourea selected from the group consisting of

### Claim 12 (depends on 10)

The pharmaceutical composition according to claim 10, characterized in that it contains 0.1 to 99% by weight of at least one lipooligourea.

### Claim 13 (depends on 10)

The pharmaceutical composition according to claim 10, characterized in that it contains a pharmaceutically acceptable carrier and/or diluent and/or aid and/or excipient.

### Claim 14 (depends on 13)

The pharmaceutical composition according to claim 13, characterized in that it contains corn starch and/or gelatin and/or lactose and/or sucrose and/or microcrystalline cellulose and/or kaolin and/or mannitol and/or dicalcium phosphate and/or sodium chloride and/or alginic acid.

### Claim 15 (depends on 10)

The pharmaceutical composition according to claim 10, characterized in that it is in a form suitable for oral and/or intravenous and/or intramuscular and/or subcutaneous and/or parenteral and/or rectal and/or topical administration.

### Claim 16 (depends on 10)

The pharmaceutical composition according to claim 10, characterized in that it is in the form of a tablet and/or capsule and/or elixir and/or suspension and/or syrup and/or gel and/or cream and/or ointment and/or suppository and/or aerosol and/or drops.

### Claim 17 (depends on 10)

The pharmaceutical composition according to claim 10, characterized in that it further contains at least one other antibacterial agent.
